drugset / Trial / NCT04627155

A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003

NCT04627155

Phase 1 Completed 20 enrolled Luye Pharma Group Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate the human tolerance and pharmacokinetics of LY03003.

Timeline

Start
2013-03-15
Primary completion
2013-05-20
Completion
2013-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 7 mg Intramuscular
Subject Rotigotine Unknown 14 mg Intramuscular

Indications